The future of antibiotics begins with discovering new combinations

Antibiotic resistance is a worldwide and growing clinical problem. With limited drug development in the antibacterial space, combination therapy has emerged as a promising strategy to combat multidrug-resistant bacteria. Antibacterial combinations can improve antibiotic efficacy and suppress antibac...

Full description

Bibliographic Details
Main Authors: Zhu, Meilin, Tse, Megan W, Weller, Juliane, Chen, Julie, Blainey, Paul C
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering
Format: Article
Language:English
Published: Wiley 2021
Online Access:https://hdl.handle.net/1721.1/136148
_version_ 1826191465239281664
author Zhu, Meilin
Tse, Megan W
Weller, Juliane
Chen, Julie
Blainey, Paul C
author2 Massachusetts Institute of Technology. Department of Biological Engineering
author_facet Massachusetts Institute of Technology. Department of Biological Engineering
Zhu, Meilin
Tse, Megan W
Weller, Juliane
Chen, Julie
Blainey, Paul C
author_sort Zhu, Meilin
collection MIT
description Antibiotic resistance is a worldwide and growing clinical problem. With limited drug development in the antibacterial space, combination therapy has emerged as a promising strategy to combat multidrug-resistant bacteria. Antibacterial combinations can improve antibiotic efficacy and suppress antibacterial resistance through independent, synergistic, or even antagonistic activities. Combination therapies are famously used to treat viral and mycobacterial infections and cancer. However, antibacterial combinations are only now emerging as a common treatment strategy for other bacterial infections owing to challenges in their discovery, development, regulatory approval, and commercial/clinical deployment. Here, we focus on discovery-where the sheer scale of combinatorial chemical spaces represents a significant challenge-and discuss how combination therapy can impact the treatment of bacterial infections. Despite these challenges, recent advancements, including new in silico methods, theoretical frameworks, and microfluidic platforms, are poised to identify the new and efficacious antibacterial combinations needed to revitalize the antibacterial drug pipeline.
first_indexed 2024-09-23T08:56:35Z
format Article
id mit-1721.1/136148
institution Massachusetts Institute of Technology
language English
last_indexed 2024-09-23T08:56:35Z
publishDate 2021
publisher Wiley
record_format dspace
spelling mit-1721.1/1361482023-10-05T19:28:34Z The future of antibiotics begins with discovering new combinations Zhu, Meilin Tse, Megan W Weller, Juliane Chen, Julie Blainey, Paul C Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. Microbiology Graduate Program Koch Institute for Integrative Cancer Research at MIT Antibiotic resistance is a worldwide and growing clinical problem. With limited drug development in the antibacterial space, combination therapy has emerged as a promising strategy to combat multidrug-resistant bacteria. Antibacterial combinations can improve antibiotic efficacy and suppress antibacterial resistance through independent, synergistic, or even antagonistic activities. Combination therapies are famously used to treat viral and mycobacterial infections and cancer. However, antibacterial combinations are only now emerging as a common treatment strategy for other bacterial infections owing to challenges in their discovery, development, regulatory approval, and commercial/clinical deployment. Here, we focus on discovery-where the sheer scale of combinatorial chemical spaces represents a significant challenge-and discuss how combination therapy can impact the treatment of bacterial infections. Despite these challenges, recent advancements, including new in silico methods, theoretical frameworks, and microfluidic platforms, are poised to identify the new and efficacious antibacterial combinations needed to revitalize the antibacterial drug pipeline. 2021-10-27T20:31:05Z 2021-10-27T20:31:05Z 2021-07 2021-08-25T16:35:31Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/136148 en 10.1111/nyas.14649 Annals of the New York Academy of Sciences Creative Commons Attribution NonCommercial License 4.0 https://creativecommons.org/licenses/by-nc/4.0/ application/pdf Wiley Wiley
spellingShingle Zhu, Meilin
Tse, Megan W
Weller, Juliane
Chen, Julie
Blainey, Paul C
The future of antibiotics begins with discovering new combinations
title The future of antibiotics begins with discovering new combinations
title_full The future of antibiotics begins with discovering new combinations
title_fullStr The future of antibiotics begins with discovering new combinations
title_full_unstemmed The future of antibiotics begins with discovering new combinations
title_short The future of antibiotics begins with discovering new combinations
title_sort future of antibiotics begins with discovering new combinations
url https://hdl.handle.net/1721.1/136148
work_keys_str_mv AT zhumeilin thefutureofantibioticsbeginswithdiscoveringnewcombinations
AT tsemeganw thefutureofantibioticsbeginswithdiscoveringnewcombinations
AT wellerjuliane thefutureofantibioticsbeginswithdiscoveringnewcombinations
AT chenjulie thefutureofantibioticsbeginswithdiscoveringnewcombinations
AT blaineypaulc thefutureofantibioticsbeginswithdiscoveringnewcombinations
AT zhumeilin futureofantibioticsbeginswithdiscoveringnewcombinations
AT tsemeganw futureofantibioticsbeginswithdiscoveringnewcombinations
AT wellerjuliane futureofantibioticsbeginswithdiscoveringnewcombinations
AT chenjulie futureofantibioticsbeginswithdiscoveringnewcombinations
AT blaineypaulc futureofantibioticsbeginswithdiscoveringnewcombinations